0.77
+0.0591(+8.28%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.73 |
| Day High | 0.79 |
| Day Low | 0.73 |
| 52-Week High | 20.6 |
| 52-Week Low | 0.7 |
| Volume | 202,505 |
| Average Volume | 1.11M |
| Market Cap | 5.43M |
| PE | -0.13 |
| EPS | -5.96 |
| Moving Average 50 Days | 7.31 |
| Moving Average 200 Days | 6.3 |
| Change | 0.06 |
If you invested $1000 in Kala Pharmaceuticals, Inc. (KALA) since IPO date, it would be worth $0.84 as of November 10, 2025 at a share price of $0.773. Whereas If you bought $1000 worth of Kala Pharmaceuticals, Inc. (KALA) shares 5 years ago, it would be worth $2.12 as of November 10, 2025 at a share price of $0.773.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
GlobeNewswire Inc.
Sep 29, 2025 12:00 PM GMT
-- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related serious adverse events observed -- -- KALA to c
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 12:00 PM GMT
ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the e
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companiesARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage